In 2010, biotech venture capital investing recovered from its 2009 low, growing three percent in dollars and eight percent in deals. That represents a significant bounce-back from 2009. That’s according to a MoneyTree Report by PricewaterhouseCoopers and the National Venture Capital Association, based on data from Thomson Reuters.
Read the full article at the FierceBiotech website.
